INOVIO Pharmaceuticals, Inc.

INOVIO Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in Plymouth Meeting, Pennsylvania, focused on the discovery, development, and commercialization of DNA medicines. The company's mission is to deliver on the promise of DNA medicine to treat and prevent diseases, including those related to human papillomavirus (HPV), various cancers, and infectious diseases.

INOVIO's core technology centers on its proprietary SynCon® DNA medicine platform and its CELLECTRA® delivery devices. This platform is designed to optimize the design and delivery of DNA medicines, enabling the body to produce its own disease-fighting tools. The company's pipeline includes candidates such as INO-3107 for Recurrent Respiratory Papillomatosis (RRP), VGX-3100 for HPV-related cervical high-grade squamous intraepithelial lesions, INO-5401 for glioblastoma multiforme, and candidates for infectious diseases like Ebola (INO-4201), COVID-19 (INO-4800), and HIV (INO-6160).

Jacqueline Shea, Ph.D., serves as the President and CEO, having been appointed in May 2022. A key development for INOVIO is its lead candidate, INO-3107, which has a Biologics License Application (BLA) under FDA review for RRP, with a Prescription Drug User Fee Act (PDUFA) target action date of October 30, 2026. The company has recently been involved in public offerings in April 2026 and reported its fourth quarter and full-year 2025 financial results in March 2026. INOVIO operates as a clinical-stage biotechnology firm with a market capitalization typically ranging between $86 million and $93 million.